公开(公告)号：US20230133671A1

公开(公告)日：2023-05-04

申请号：US17904570

申请日：2021-02-19

Applicant: EPIZYME, INC.

Inventor： Maria Alejandra RAIMONDI ,  Jennifer Anne TOTMAN ,  Vinny MOTWANI ,  Katherine Louise COSMOPOULOS ,  John LAMPE

IPC: A61K31/496 ,  A61K31/407 ,  A61K45/06

Abstract: The present disclosure provides SETD2 protein inhibitors, and methods, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and, optionally, a second therapeutic agent, wherein the second therapeutic agent comprises one or more glucocorticoid receptor agonists, one or more immunomodulatory drugs, one or more proteasome inhibitors, one or more Bcl-2 inhibitors, one or more pleiotropic pathway modulators, one or more XPO1 inhibitors, one or more histone deacetylase inhibitors, or one or more EZH2 inhibitors, or a combination thereof.

公开(公告)号：US20230049113A1

公开(公告)日：2023-02-16

申请号：US17294959

申请日：2019-11-26

Applicant: EPIZYME, INC.

Inventor： Michael THOMENIUS ,  Katherine Louise COSMOPOULOS ,  Jennifer Anne TOTMAN

IPC: A61K31/404 ,  A61P35/00 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/438 ,  A61K31/541 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/422 ,  A61K31/519 ,  A61K31/4709 ,  A61K31/551 ,  A61K31/454 ,  A61K31/55 ,  A61K31/439 ,  A61K31/506 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4725 ,  A61K31/5386 ,  A61K31/427 ,  A61K31/415 ,  A61K31/4995 ,  A61K31/4196 ,  A61K31/4155 ,  A61K31/517 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/499

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

公开(公告)号：US20240299352A1

公开(公告)日：2024-09-12

申请号：US18568368

申请日：2022-06-08

Applicant: Epizyme, Inc.

Inventor： Maria Alejandra RAIMONDI ,  Jenniffer Anne TOTMAN ,  Vinny MOTWANI ,  Katherine Louise COSMOPOULOS ,  Dorothy BRACH ,  Daniel T. DRANSFIELD

IPC: A61K31/404 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/404 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure provides SETD2 protein inhibitors, and methods, uses, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and a Second Therapeutic Agent, wherein the Second Therapeutic Agent comprises one or more BTK inhibitors, one or more anti-CD20 monoclonal antibodies, one or more alkylating agents, one or more topoisomerase II inhibitors, one or more vinca alkaloids, one or more platinum-based drugs, one or more nucleoside anticancer agents, one or more PI3K inhibitors, one or more CDK4/6 inhibitors, one or more CARM1 inhibitors, one or more inhibitors of enzymes of DNA damage repair, one or more SYK inhibitors, or one or more MEK inhibitors, or a combination thereof.